Inventor · disambiguated record
Wolfgang Brysch
Also filed as: BRYSCH WOLFGANG
17 granted patents·15 pending applications·120 citations·filing 1994–2024
92Inventor score
Top patents by PatentIndex Score
32 records- 0188US7667027B2Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-β (TGF-β)BIOGNOSTIK GES·Filed 2006·Granted Feb 23, 2010·15 cites·2 claims
- 0284US6455689B1Antisense-oligonucleotides for transforming growth factor-β (TGF-β)BIOGNOSTIK GES·Filed 1994·Granted Sep 24, 2002·49 cites·6 claims
- 0382US11497760B2Method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agentsATHENION AG·Filed 2017·Granted Nov 15, 2022·2 cites·7 claims
- 0481US8629117B2Method for stimulating the immune systemSCHLINGENSIEPEN KARL-HERMANN·Filed 2007·Granted Jan 14, 2014·2 cites·6 claims
- 0575US11007192B2Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosisMETRIOPHARM AG·Filed 2017·Granted May 18, 2021·2 cites·11 claims
- 0670US2025051288A1Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedioneMETRIOPHARM AG·Filed 2024·Application pending·0 cites
- 0767US11207256B2Method for solubilizing poorly water-soluble cosmetic agentsATHENION AG·Filed 2018·Granted Dec 28, 2021·1 cites·13 claims
- 0866US7563778B2Antisense oligonucleotide preparation methodBIOGNOSTIK GES·Filed 2004·Granted Jul 21, 2009·2 cites·5 claims
- 0965US6365345B1Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a roleBIOGNOSTIK GESELLSCAHFT FUER B·Filed 1994·Granted Apr 2, 2002·30 cites·5 claims
- 1064US9079863B2Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said formsMETRIOPHARM AG·Filed 2014·Granted Jul 14, 2015·1 cites·16 claims
- 1163US10258620B2Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said formMETRIOPHARM AG·Filed 2015·Granted Apr 16, 2019·1 cites·2 claims
- 1259US2025064801A1Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of congenital muscular dystrophiesMETROPHARM AG·Filed 2023·Application pending·0 cites
- 1359US2025064800A1Combination of budesonide and 5-amino-2,3-dihydro-1,4-phthalazinedioneMETROPHARM AG·Filed 2023·Application pending·0 cites
- 1458US12122753B2Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedioneMETRIOPHARM AG·Filed 2019·Granted Oct 22, 2024·0 cites·8 claims
- 1558US8772294B2Crystalline forms for 5-amino-2, 3-dihydrophthalazine-1, 4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said formsBREU JOSEF·Filed 2011·Granted Jul 8, 2014·1 cites·17 claims
- 1658US6972171B1Antisense oligonucleotide preparation methodBIOGNOSTIK GES·Filed 1998·Granted Dec 6, 2005·14 cites·9 claims
- 1755US2025032486A1Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infectionsMETROPHARM AG·Filed 2022·Application pending·0 cites
- 1852US11111218B2Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dioneMETRIOPHARM AG·Filed 2017·Granted Sep 7, 2021·0 cites·9 claims
- 1951US2023241060A1Glucocorticoid-sparing agentMETRIOPHARM AG·Filed 2021·Application pending·0 cites
- 2049US2023218614A1Compound for the treatment of coronaviral infectionsMETRIOPHARM AG·Filed 2021·Application pending·0 cites
- 2148US2023113516A15-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injuryMETRIOPHARM AG·Filed 2021·Application pending·0 cites
- 2248US2003040499A1Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-beta (TGF-beta)BIOGNOSTIK GES·Filed 2002·Application pending·0 cites
- 2347US2023210786A1Method for solubilizing natural, endogenous and synthetic cannabinoidsATHENION AG·Filed 2021·Application pending·0 cites
- 2447US2023053455A1Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseasesMETRIOPHARM AG·Filed 2021·Application pending·0 cites
- 2546US2023061223A1Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseasesMETRIOPHARM AG·Filed 2021·Application pending·0 cites
- 2642US11203575B2Methhod for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dioneMETRIOPHARM AG·Filed 2017·Granted Dec 21, 2021·0 cites·4 claims
- 2740US2024075029A1Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infectionMETRIOPHARM AG·Filed 2021·Application pending·0 cites
- 2839US2020113824A1Dispensing cap containing a solubilisate of a pharmaceutically active agent or dietary supplementATHENION AG·Filed 2018·Application pending·0 cites
- 2935US2019084757A1Beverage preparation capsule for delivery of a solubilisateBRYSCH EKKEHARD·Filed 2017·Application pending·0 cites
- 3032US2006252716A1Method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia"SCHLINGENSIEPEN KARL-HERMANN·Filed 2001·Application pending·0 cites
- 3131US10588896B2Agents for the treatment of retroviral infectious diseasesIMMUNOLOGIK GMBH·Filed 2015·Granted Mar 17, 2020·0 cites·3 claims
- 3228US7326783B2Pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasmsBIOGNOSTIK GES·Filed 1994·Granted Feb 5, 2008·0 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Wolfgang Brysch files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →